Tissue-Engineered Disease Modeling of Lymphangioleiomyomatosis Exposes a Therapeutic Vulnerability to HDAC Inhibition.
Pietrobon A, Yockell-Lelièvre J, Melong N, Smith LJ, Delaney SP, Azzam N, Xue C, Merwin N, Lian E, Camacho-Magallanes A, Doré C, Musso G, Julian LM, Kristof AS, Tam RY, Berman JN, Shoichet MS, Stanford WL.
Pietrobon A, et al. Among authors: shoichet ms.
Adv Sci (Weinh). 2023 Sep;10(26):e2302611. doi: 10.1002/advs.202302611. Epub 2023 Jul 3.
Adv Sci (Weinh). 2023.
PMID: 37400371
Free PMC article.